A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 6, 2016, Pages 832-838

  Jindani, A ^a   Borgulya, G ^a   Westermann De Patino, I ^b   Gonzales, T ^b   De Fernandes, R A ^b   Shrestha, B ^c   Atwine, D ^d   Bonnet, M ^d   Burgos, M ^e   Dubash, F ^a   Patel, N ^a   Checkley, A M ^a   Harrison, T S ^a   Mitchison, D ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b Kuratorium Tuberkulose in der Welt   (Bolivia)

^c German Nepal Tuberculosis Project   (Nepal)

^d EPICENTRE   (France)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Rifampicin; Toxicity; Treatment; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SCREENING; DRUG WITHDRAWAL; ESOPHAGUS CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SKIN TOXICITY; TREATMENT DURATION; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHAMBUTOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84966539269     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0577     Document Type: Article

References (20)

1. US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS Table for grading severity of adult adverse experiences Bethesda, MD, USA: US Department of Health and Human Services, 1992.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Guidelines (ICH E2A) Clinical safety data management definitions and standards for expediting reporting Geneva, Switzerland: ICH, 1994.
3. Mitchison D A.Role of individual drugs in the chemotherapy of tuberculosis Int J Tuberc Lung Dis 2000; 4: 796-806.
4. World Health Organization Treatment of tuberculosis: guidelines 4th ed WHO/HTM/TB/2009.420 Geneva, Switzerland: WHO, 2010.
5. Jindani A, Nunn A J, Enarson D E.Two eight-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial Lancet 2004; 364: 1244-1251.
6. Fox W.Whither short-course chemotherapy? Br J Dis Chest 1981; 75: 331-357.
7. Peloquin C.What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5.
8. de Steenwinkel J E, Aarnoutse R E, de Knegt G J, et al Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model Am J Respir Crit Care Med 2013; 187: 1127-1134.
9. Boeree M J, Diacon A H, Dawson R, et al., on behalf of the PanACEA Consortium A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis Am J Respir Crit Care Med 2015; 191: 1058-1065.
10. Kochar D K, Aseri S, Sharma B V, Bumb R A, Mehta R D, Purohit S K.The role of rifampicin in the management of cutaneous leishmaniasis QJM 2000; 93: 733-737.
11. SelimMM, Kandil E.Rifampicin in the treatment of cutaneous leishmaniasis J Kuwait Med Assoc 1972; 6: 159-166.
12. Cascio A, Scarlata F, Giordano S, Antinori S, Colomba C, Titone L.Treatment of human brucellosis with rifampin plus minocycline J Chemother 2003; 15: 248-252.
13. Drancourt M, Stein A, Argenson J N, Roiron R, Groulier P, Raoult D.Oral treatment of staphylococcus spp infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin J Antimicrob Chemother 1997; 39: 235-240.
14. Kreis B, Pretet S, Birenbaum J, et al Two three-month treatment regimens for pulmonary tuberculosis Bull Int Union Tuberc 1976; 51(1): 71-75.
15. Verbist L.Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy I.variation of rifampicin serum levels (947 determinations) Respiration 1971; 28 (Suppl): 7-16.
16. Steingart K R, Jotblad S, Robsky K, et al Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review Int J Tuberc Lung Dis 2011; 15: 305-316.
17. Sarma G R, Immanuel C, Kailasam S, Narayana A S L, Venkatesan P.Rifampin-induced release of hydrazine from isoniazid A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin Am Rev Respir Dis 1986; 133: 1072-1075.
18. Pande JN, Singh S P N, KhilnaniG C, Tandon R K.Risk factors for hepatotoxicity from anti-tuberculosis drugs: a case-control study Thorax 1996; 51: 132-136.
19. Aarnoutse R E, Kibiki G S, Reither K, et al HIGHRIF2: a phase II trial comparing 10, 15 and 20 mg/kg rifampicin for two months 7th International Workshop on Clinical Pharmacology of TB Drugs, 5 September 2014, in Washington DC, USA http://www infectiousdiseasesonl ine.com/7th-tb-pkworkshop-presentations/Accessed March 2016
20. Boeree M, Hoelscher M.High-dose rifampin, SQ 109 and moxifloxacin for treating TB: the PanACEA MAMS-TB Trial Conference on Retroviruses and Opportunistic Infections, 23-February 2015, Seattle, WA, USA [Abstract 95LB] http://www.croiconference.org/sessions/high-dose-rifampin-sq109-And-moxifloxacin-treating-tb-panacea-mams-tb-trial Accessed March 2016